CJC-1295Secretagogue Peptide
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Elite Edge Biotech 8.5/10 COA ✓Ships: USVisa · Mastercard Verification & shipping8.5/10 COA ✓Ships: USVisa · Mastercard | $49.50 | $49.50Checked jul 28, 2026 | Jul 28, 2026 | Buy CJC-1295 from Elite Edge Biotech |
| Refined BioLabs 8.5/10 COA ✓Ships: USVisa · American Express Verification & shipping8.5/10 COA ✓Ships: USVisa · American Express | $53.99 | $53.99Checked jul 30, 2026 | Jul 30, 2026 | Buy CJC-1295 from Refined BioLabs |
| Pepsynth Labs 5.5/10 COA ✓Ships: USApple Pay · Google Pay Verification & shipping5.5/10 COA ✓Ships: USApple Pay · Google Pay | $54.00 | $54.00Checked today | Today | Buy CJC-1295 from Pepsynth Labs |
| Atomik Labz 7/10 COA ✓Ships: US + CanadaPayment not verified Verification & shipping7/10 COA ✓Ships: US + CanadaPayment not verified | $33.75 | $67.50Checked 3 days ago | 3 days ago | Buy CJC-1295 from Atomik Labz |
| Alpha Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $33.99 | $67.98Checked jul 31, 2026 | Jul 31, 2026 | Buy CJC-1295 from Alpha Peptides |
| RUO Market 5.5/10 COA on requestShips: USPayment not verified Verification & shipping5.5/10 COA on requestShips: USPayment not verified | $35.99 | $71.98Checked 5 days ago | 5 days ago | Buy CJC-1295 from RUO Market |
Research details
CJC-1295 — research data
Overview
About CJC-1295
Mechanism of action
GHRH analogue with Drug Affinity Complex that covalently binds albumin, dramatically extending half-life. Causes sustained GH release ('GH bleed') vs. pulsatile pattern.
Safety profile
Water retention, lethargy, joint pain, insulin resistance, potential blunting of natural GH pulsatility with prolonged use. · Human PK data available; one unexplained death in trials (possibly unrelated); longer half-life
Storage
Stability & handling
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Active malignancy — sustained GH/IGF-1 elevation.
One unexplained death reported in Phase 1 trials (possibly unrelated). Long half-life (~1 week) complicates dose adjustments.
Type 2 diabetes — extended GH exposure worsens insulin sensitivity more than No-DAC variant.
Research products are not for human use. Looking for clinician-supervised care instead? Compare licensed US telehealth programs that may offer provider-guided peptide protocols when clinically appropriate.
Compare supervised options →Related pages
More on CJC-1295
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- CJC-1295 is a tetrasubstituted GHRH(1-29) analogue bearing a maleimido-propionyl group at its C-terminus that covalently binds to endogenous serum albumin after injection — extending its half-life to approximately 6–8 days compared to the minutes-long half-life of native GHRH, enabling once-weekly dosing.
- The landmark Phase 1/2 human study (JCEM 2006, Teichman et al.) demonstrated that a single subcutaneous injection of CJC-1295 at 30–60 µg/kg produced sustained, dose-dependent increases in GH (2–10 fold) and IGF-1 (1.5–3 fold) lasting up to 14 days, with excellent tolerability and no serious adverse events in healthy adults.